Llwytho...
Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis
Ruxolitinib is a recommended second-line treatment for the prevention of thrombosis in patients with polycythemia vera who become resistant or intolerant to hydroxyurea; however, evidence regarding its efficacy in terms of thrombosis reduction is uncertain. We searched Medline, Embase, and archives...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Blood Adv |
|---|---|
| Prif Awduron: | , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
American Society of Hematology
2020
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6988397/ https://ncbi.nlm.nih.gov/pubmed/31985808 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001158 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|